BioCentury
ARTICLE | Clinical News

Da Volterra's DAV132 meets in Phase I for antibiotic-induced dysbiosis

February 2, 2018 8:36 PM UTC

Da Volterra (Paris, France) reported data from the open-label, French Phase I DAV132-CL-1002 trial in 44 healthy volunteers showing that DAV132 met the primary endpoint by effectively capturing residual moxifloxacin in the colon. Specifically, co-administration of thrice-daily DAV132 with a five-day regimen of the fluoroquinolone antibiotic moxifloxacin reduced exposure of the lower intestinal microbiota to free moxifloxacin by 99% compared to moxifloxacin alone. Additionally, there was no significant difference in plasma pharmacokinetics of moxifloxacin between the co-administration arm and the moxifloxacin alone arm. DAV132 is an oral encapsulated non-specific adsorbent consisting of pellets targeted to deliver activated charcoal to the late ileum, cecum and colon to capture antibiotic residues that is intended to prevent antibiotic-induced dysbiosis. The data were published in the Journal of Infectious Diseases in November...

BCIQ Company Profiles

Da Volterra